Health-Economic Aspects of MCS Therapy
Implant Cost REMATCH HeartMate II DT Trial p-Value N 54 98 <0.01 Cost ($) 384,260 ± 340,456 193,812 ± 71,027 Median ($) 245,445 186,156 Heart transplant without an LVAD bridge…
Psychosocial Considerations of Mechanical Circulatory Support: Decision Making, Behavioral Evaluation, Quality of Life, Caregivers, and End of Life
Fig. 45.1 Depiction of benefits and risks through 1 year after mechanical circulatory support Inherent to the ethical considerations of shared decision making regarding MCS as a treatment option are…
Pump Removal After Myocardial Recovery During Left Ventricular Assist Device Support
Fig. 34.1 Intraoperative view of individually designed titanium plug inserted after HeartWare HVAD explantation through left lateral thoracotomy Fig. 34.2 Thoracic X-ray after removal of HeartMate II showing the titanium…
MCS Candidate Selection Criteria
Fig. 4.1 Patient selection workflow. HF heart failure; EF ejection fraction; OMM optimal medical management; CRT continuous replacement therapy; 6MWT 6-minutes walking test; PCP pulmonary capillary pressure; SBP systolic blood…
Tricuspid Valve Regurgitation and Right Ventricular Dysfunction During Left Ventricular Assist Device Implantation
Fig. 20.1 Tricuspid regurgitation severity frequency distribution for 137 patients who did not receive a concurrent tricuspid valve procedure during LVAD implantation [5]. Figure demonstrates tricuspid valve regurgitation severity; (a)…
Intraoperative Anticoagulation and Coagulation Management
Procedure/system Heparin [IU/Kg]a Target ACT [s]b Open CPB circuit 400 400–480 MECC system (complete heparin coating) 150–300 300–400 ECLS (complete biocompatible coating) 50–100 160–180c ECLS (noncoated) 100–150 180–220c “Off-pump” 100–150…
The EUROMACS Registry of Patients Who Receive Mechanical Circulatory Support: Role and Perspectives
Fig. 58.1 Kaplan Myer analysis: overall survival of all MCS devices The overall actuarial survival of 2850 patients receiving a primary implantation with a MCS device at 6 months, 1,…
Bridge to Transplant and Destination Therapy Strategies in the United States
Fig. 11.1 Kaplan-Meier analysis of survival for transplant-ineligible patients who received a left ventricular assist device (LVAD) versus optimal medical therapy (Reproduced, with permission, from Rose et al. [3]) This…
Concomitant Noncardiac Surgery During Mechanical Circulatory Support: Management of Therapy
© Springer International Publishing Switzerland 2017Andrea Montalto, Antonio Loforte, Francesco Musumeci, Thomas Krabatsch and Mark S. Slaughter (eds.)Mechanical Circulatory Support in End-Stage Heart Failure10.1007/978-3-319-43383-7_51 51. Concomitant Noncardiac Surgery During Mechanical Circulatory Support: Management of Therapy Rachel A. Beaupré1 and Jeffrey A. Morgan2 …
Ischemic and Hemorrhagic Stroke
© Springer International Publishing Switzerland 2017Andrea Montalto, Antonio Loforte, Francesco Musumeci, Thomas Krabatsch and Mark S. Slaughter (eds.)Mechanical Circulatory Support in End-Stage Heart Failure10.1007/978-3-319-43383-7_46 46. Ischemic and Hemorrhagic Stroke Rachel A. Beaupré1 and Jeffrey A. Morgan2 (1) Center for Circulatory Support, Cardiac…
